Replies to post #439346 on Amarin Corp Plc (AMRN)

[JRoon71]

Sure, they could do that. But a settlement does nothing to remove the other 7 generics from the market. Only a court decision can do this.

[Number sleven]

TTE, Infringement by Hikma doesn't help. They need to invalidate the label. In GSK v Teva they used expert testimony to do this. The "skinny label" failed to carve out the patented indication because there was no way to separate one from the other. I think they are going to do the same thing in Amarin v Hikma. If you want I can dig through the ruling and direct you to the relevant section.
Sleven,